News
MNKD
4.160
+1.22%
0.050
Weekly Report: what happened at MNKD last week (0415-0419)?
Weekly Report · 1d ago
MNKD Makes Notable Cross Below Critical Moving Average
NASDAQ · 04/16 17:39
Weekly Report: what happened at MNKD last week (0408-0412)?
Weekly Report · 04/15 10:32
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)
TipRanks · 04/09 02:30
Weekly Report: what happened at MNKD last week (0401-0405)?
Weekly Report · 04/08 10:35
MANNKIND CORP - CREDIT AND SECURITY AGREEMENT WITH MIDCAP FINANCIAL TRUST REPAID IN FULL FOR APPROXIMATELY $31.6 MLN
Reuters · 04/03 10:07
MannKind Announced That It Has Repaid In Full All Outstanding Indebtedness Under Both Its Credit And Security Agreement With Midcap Financial Trust And Its Convertible Promissory Note Issued To Mann Group LLC
Benzinga · 04/03 10:06
Press Release: MannKind Repays Certain Debt Obligations
MannKind Corporation has repaid in full all outstanding indebtedness. Total debt reduced since December 31, 2023 is approximately $41.8 million. MannKind is a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases.
Dow Jones · 04/03 10:00
MannKind Repays Certain Debt Obligations
MannKind Corporation is a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases. The company has repaid in full all outstanding indebtedness. MannKind is a subsidiary of MannKind Corp.
Barchart · 04/03 05:00
Weekly Report: what happened at MNKD last week (0325-0329)?
Weekly Report · 04/01 10:34
Mannkind: Statement of changes in beneficial ownership of securities
Press release · 03/30 02:47
Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?
NASDAQ · 03/29 15:30
MannKind Appoints Prentiss as CFO, Binder to Retire
Biopharma company MannKind appoints Christopher Prentiss as chief financial officer. Steven Binder will remain at MannKind through the end of the year. Binder announced he planned to retire. Incoming CFO will receive a base salary of $460,000.
Dow Jones · 03/26 20:38
MannKind Corp Announces CFO Transition and New Compensation Plan
TipRanks · 03/26 20:23
MannKind CFO Steven Binder to retire
Healthcare MannKind CFO Steven Binder to retire April 22, 2024. Binder plans to remain at MannKind through the end of the year. Christopher Prentiss has been appointed as CFO. MannKind Corporation (MNKD) Stock to be listed on Nasdaq.
Seeking Alpha · 03/26 20:13
*MannKind: Christopher Prentiss Appointed Chief Fincl Officer, Effective April 22 >MNKD
Dow Jones · 03/26 20:07
*MannKind: Steven Binder Announces Planned Retirement and Is Appointed Executive Vice Pres, Special Projects, Effective April 22 Through Dec 31 >MNKD
Dow Jones · 03/26 20:07
Press Release: MannKind Announces CFO Transition
MannKind Announces CFO Transition. Steven B. Binder will retire from his position as Chief Financial Officer, effective April 22, 2024. Christopher Prentiss has been appointed as the new CFO. MannKind is a company focused on the development and commercialization of inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases.
Dow Jones · 03/26 20:05
Weekly Report: what happened at MNKD last week (0318-0322)?
Weekly Report · 03/25 10:37
Weekly Report: what happened at MNKD last week (0311-0315)?
Weekly Report · 03/18 10:35
More
Webull provides a variety of real-time MNKD stock news. You can receive the latest news about Mannkind through multiple platforms. This information may help you make smarter investment decisions.
About MNKD
MannKind Corporation is a biopharmaceutical company. It is focused on the development and commercialization of inhaled therapeutic products for patients with endocrine and orphan lung diseases. Its technologies include Technosphere dry-powder formulations and Dreamboat inhalation devices, which offers delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation. Its products include Afrezza (insulin human) Inhalation Powder and the V-Go wearable insulin delivery device. The Afrezza (insulin human) Inhalation Powder is an inhaled insulin indicated to enhance glycemic control in adults with diabetes. The V-Go wearable insulin delivery device provides subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease pipeline includes Tyvaso DPI (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).